Abeona Therapeutics (ABEO) Q2 2024 earnings summary

Executive summary

• Significant progress made in addressing FDA's Complete Response Letter (CRL) for pz-cel BLA, with nearly all CMC issues resolved and only two validation items outstanding; no new clinical trials or data requested by FDA.

• BLA resubmission for pz-cel is on track for the second half of 2024, following a successful Type A meeting with FDA; commercial launch preparations, including cGMP facility readiness, site onboarding, and payer engagement, are advancing.

• Entered a non-exclusive agreement with Beacon Therapeutics for AAV204 capsid evaluation in ophthalmology gene therapies.

• Preclinical pipeline includes AAV-based gene therapies for genetic eye diseases, with pre-IND meetings completed.

• Completed a $75 million underwritten offering in May 2024, strengthening the balance sheet and extending cash runway.

Financial highlights

• Cash, cash equivalents, short-term investments, and restricted cash totaled $123 million as of June 30, 2024, up from $62.7 million at March 31, 2024.

• Net income for Q2 2024 was $7.4 million, including a $24.9 million gain from warrant liability remeasurement, compared to a net loss of $16.7 million in Q2 2023.

• Research and development expenses were $9.2 million for Q2 2024, up from $8.5 million in Q2 2023; general and administrative expenses rose to $8.6 million from $5 million, mainly due to commercial and launch preparation.

• Net cash used in operating activities was $12.7 million for Q2 2024.

• Total revenue was nil for Q2 2024, compared to $3.5 million in Q2 2023, due to absence of milestone payments.

Outlook and guidance

• Sufficient financial resources, including a $50 million credit facility, are expected to fund operations into 2026, excluding potential pz-cel revenue or PRV proceeds.

• BLA resubmission for pz-cel is expected in the second half of 2024; FDA review anticipated to take six months if accepted.

• Commercial launch of pz-cel targeted approximately three months after potential approval.

• Continued investment in commercialization and R&D expected to result in ongoing operating losses for the foreseeable future.